Lionheart Health, Inc., a leader in bioelectric regeneration and longevity biotechnology, announced the filing of a non-provisional U.S. patent for its Bioelectric-Enhanced Klotho Nanoflowers, a platform technology designed to reverse aging and extend healthspan. The patent covers a system integrating nanoflower-shaped nanoparticles, bioelectric stimulation sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform centers on engineered nanoflowers—hybrid nanoparticles that upregulate Klotho, a longevity-associated protein, restore mitochondrial function by enhancing ATP production and reducing oxidative stress, and deliver targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators. These nanoflowers act as nanozyme catalysts that reduce reactive oxygen species and enhance regenerative signaling when activated by precise bioelectric patterns.
Howard J. Leonhardt, Founder and CEO of Lionheart Health, stated, 'This invention represents the convergence of three powerful emerging technologies—bioelectric signaling, nanomedicine, and Klotho modulation. Our goal is to reverse biological age at the cellular level and enhance healthspan safely and affordably.'
The nanoflowers are designed to respond to Lionheart's proprietary bioelectric stimulation sequences, increasing cellular uptake, intracellular transport, and activation of catalytic and genetic payloads. Bioelectric stimulation opens ion channels, improves endocytosis, directs nanoflowers toward mitochondria, and triggers therapeutic payload release. Klotho expression increases through nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways, creating a combined therapeutic benefit.
The system is designed for system-wide healthspan improvement, including mitochondrial biogenesis via activation of PGC-1α, NRF1/2, and TFAM; reduction of cellular senescence by lowering oxidative stress; and stabilization of biological age through combined mitochondrial repair and Klotho enhancement.
Klotho is recognized as a key longevity molecule, with decreased levels associated with accelerated aging, cognitive decline, inflammation, and kidney dysfunction. Lionheart's platform enables targeted Klotho delivery and activation inside cellular compartments most responsible for aging. Dr. Leslie Miller, Chief Medical Officer, noted, 'Bioelectric-enhanced Klotho nanoflowers give us a programmable tool to address root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity. This filing marks a major milestone.'
The patent adds to Lionheart's IP portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and Klotho-based therapies. Optional components include closed-loop adaptive control, multi-modal integration with peptides and red light, and repeat cycle integration for clinical studies. Lionheart is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program.
Lionheart Health, Inc. develops clinically validated systems for organ repair, cellular rejuvenation, and age reversal. More information is available at LionheartHealthStim.com, LionheartLongevity.com, and LeonhardtVentures.com.
